Post hoc subgroup analysis of the RAISE trial (1373 patients with acute ischaemic stroke): the relative efficacy and safety of reteplase vs alteplase did not differ by baseline fibrinogen (low, normal or high); findings need validation.
Secondary analysisn = 1,373
Wang et al. Efficacy and Safety of Reteplase Versus Alteplase in Acute Ischemic Stroke Based on Fibrinogen Levels: The RAISE Trial Subgroup